Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643044 | 0.90 | CA2 (0.45) | CA12CA2TDP1MAOBMAPT | |
| SCHEMBL6232289 | 0.90 | CA12 (0.45) | CA12CA2TDP1MAOBMAPT | |
| SCHEMBL14462523 | 0.90 | CA12 (0.45) | CA12CA2TDP1MAOBMAPT | |
| SCHEMBL6130757 | 0.81 | KMT2A (0.49) | SMN1; SMN2PTPN1HTTTBXAS1 | |
| SCHEMBL6233312 | 0.81 | CYP2A6 (0.49) | CA12CA2TDP1MAOBMAPT | |
| SCHEMBL11777951 | 0.77 | TDP1 (0.53) | TDP1MAOBMAPTENPP3ENPP1 | |
| SCHEMBL6130765 | 0.76 | MTNR1A (0.52) | CA12CA2TDP1MAPTSMN1; SMN2 | |
| SCHEMBL6130728 | 0.73 | KDM4E (0.54) | MAPTLMNAHTTALDH1A1TBXAS1 | |
| SCHEMBL6234706 | 0.71 | CA2 (0.80) | CA12CA2TDP1MAOBENPP1 | |
| SCHEMBL3319330 | 0.70 | IDO1 (0.46) | CA12CA2MAPTPTPN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009060030-A1 | HETEROARYL-SUBSTITUTED 2-PYRIDINYLMETHYLAMINE DERIVATIVES | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2009-05-14 | — | — | WO | disclosed |
| EP-2058306-A1 | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives | SCHWARZ PHARMA AG (DE) | 2009-05-13 | — | — | EP | disclosed |
| EP-1069122-B1 | PROCESS FOR PRODUCING 5-HYDROXYBENZO [b]THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | SHIONOGI & CO (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1084711-B1 | REMEDIES FOR THE TREATMENT OF ITCHING CONTAINING PGD2 ANTAGONISTS | SHIONOGI & CO (JP) | 2005-05-11 | — | — | EP | disclosed |
| EP-1528060-A1 | Process for preparing 5-hydroxy[b]thiophene-3-carboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2005-05-04 | — | — | EP | disclosed |
| EP-1069123-B1 | PROCESS FOR PRODUCING BENZOTHIOPHENECARBOXYLIC ACID AMIDE DERIVATIVES | SHIONOGI & CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | SHIONOGI & CO., LTD. | 2003-02-06 | — | — | US | disclosed |
| US-6506789-B2 | For prophylaxis and therapy of itching derived from contact dermatitis, allergic conjunctivitis, urticaria, atopic dermatitis | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| US-6495702-B2 | SPECIFIC PGD2 ANTAGONISTS; STARTING MATERIALS FOR PRODUCING DRUGS | SHIONOGI & CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020161242-A1 | Process for preparing benzothiophenecarboxamide derivatives | HONMA TSUNETOSHI (JP) | 2002-10-31 | — | — | US | disclosed |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HONMA TSUNETOSHI (JP) | 2002-02-28 | — | — | US | disclosed |
| US-6346628-B1 | REACTING 4-MERCAPTOPHENOL WITH A PROPARYGL GOUP AND PROTECTION OF HYDROXYL GROUP, OXIDIZING THE PRODUCT, AND THERMAL REARRANGEMENT TO CYCLIZE, FOLLOWED BY FURTHER OXIDATION | SHIONOGI & CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HONMA TSUNETOSHI (JP) | 2002-02-07 | — | — | US | disclosed |
| US-6320060-B1 | INTRODUCING PROPARGYL GROUP INTO 4-MERCAPTOPHENOL, PROTECTING HYDROXYL GROUP, OXIDIZING COMPOUND, SUBJECTING TO THERMAL REARRANGEMENT REACTION, SUBJECTING TO STEPWISE OXIDATION OF HYDROXYMETHYL GROUP AND OPTIONALLY DEPROTECTION | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1084711-A1 | REMEDIES FOR ITCHING CONTAINING PGD 2? ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-1069123-A1 | PROCESS FOR PRODUCING BENZOTHIOPHENECARBOXYLIC ACID AMIDE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-1069122-A1 | PROCESS FOR PRODUCING 5-HYDROXYBENZO b]THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-6083974-A | BENZOTHIOPHENECARBOXAMIDE CONTAINING NORPINANE RING IS USEFUL FOR PREVENTING NASAL BLOCKAGE | SHIONOGI & CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0944614-A1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025919-A1 | BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD2 ANTAGONISTS COMPRISING THEM | SHIONOGI & CO., LTD. (JP) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HPD, PTGDR2, PTGS2 | CA12 4348/4885CA2 862/4885TDP1 3016/4885 |
| US-20020161242-A1 | Process for preparing benzothiophenecarboxamide derivatives | PGD, HPD, PTGS2 | CA12 3200/4885CA2 592/4885TDP1 3653/4885 |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HPD, PTGDR2, PTGS2 | CA12 4348/4885CA2 862/4885TDP1 3016/4885 |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | CA12 2382/4885CA2 368/4885TDP1 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.